Stanford researchers have discovered the first of its kind gene therapy vector to treat eye diseases of the non-pigmented ciliary epithelium cells (NPCECs).
To manage the development and progression of glaucoma, researchers at Stanford University have developed a biocompatible suprachoroidal spacer implant.